The DCGI has directed state and UT drug controllers to monitor levels of the potentially carcinogenic NDMA in Ranitidine, an ...

The Central Drugs Standard Control Organisation (CDSCO) has directed all state and union territory drug regulators to ensure ...

CDSCO is monitoring ranitidine due to NDMA, a potential carcinogen. The DTAB recommended a study on the drug's safety, ...

Manufacturers have been asked to adopt risk-based approaches, including stricter testing protocols, revised storage ...

NDMA is classified as a Group 2A carcinogen by the International Agency for Research on Cancer (IARC), indicating it is a ...

The Central Drugs Standard Control Organisation has flagged concerns of a cancer-causing impurity in Ranitidine -- a commonly ...

The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services, has issued a ...